Hemostasis Flashcards
Cofactors are enzymes except..
V & VIII
Vitamin K derivates
II, VII, IX & X
I
1 Fibrinogen
source - liver
clot formation
II
2 prothrombin
liver/platelets
Vit K derivative
active forme activates I, V, VII, XIII
III
3 Tissue Factor
Vascular wall
cofactor with VII
*activates clotting cascade, procoagulant
IV
4 Calcium
diet
promotes clotting
V
5 Proaccelerin
liver
X cofactor
VI
6 - no assignment
VII
7 - Proconvertin
liver
vit K derivative
activates IX and X
VIII
8 - Antihemophiliac
liver
activates X
IX
9 - Christmas
liver
vit K derivative
X
10 - Struart Power
liver
vit k derivative
activates II
XI
11 Plasma Thromboplastin
liver
activates IX
XII
12 Hageman
liver
activates XI
XIII
13 Fibrin stablizing
liver
links fibrin
vWF
Von Willibrand Factor
endothelial layer
adhesion, procoagulant
Endothelial Vasocontrictors
ADP
Thromboxane A2
Serotonin
Endothelial Vasodilators
NO
Prostacyclin
Endothelial Coagulation Inhibitor
Tissue Factor Pathway Inhibitor
Subendothelial - Tunica Media
thrombogenic
collagen and fibronectin
II cont…
Pothrombin –> Thrombin is vital to both pathways
thrombin activates V, VII and IX, “the anticoag”
CBT Initiation
TF and VIII complex activate common and intrinsic pathways
CBT Amplification
platelets activated
CBT Propogation
bursts of thrombin
Fibrinolytic System
no more plugging needed
protein C & S inhibit III, V and VIII
Platelet
formed at marrow, no nucleus
produces thrombin
alpha and dense granules
Alpha granules
vWF
fibrinogen, fibronectin
platelet factor 4
platelet growth factor
Dense Granules
serotonin ADP ATP histamine epinephrine
Intrinsic Clotting Pathway
vessel damage
initiated by prekalikrein and HMWK
XII, XI, IX and VIII
Extrinsic Clotting Pathway
outside injury
FIII tissue factor activates
factor VII
Common Pathway
formation of prothrombinase complex
stable clot
X, V, II, XIII
bleeding time
3-7 mins
platelet count
150,000-350,000
<100,000 = thrombocytopenic
<50,000 = surgical risk
<20,000 = bleeding risk
dose 1 pack/kg
PT
prothrombin time 12-14 sec III, VII & X, V, II, I *prolonged with extrinsic or common pathway disorder altered by coumadin derivates
aPTT
25-32 sec XII, XI, IX, VIII X, V, II, I, XIII *prolonged with intrinsic or common pathway disorder -heparin and lovenox
cryoprecipitate
fibrinogen < 80-100 mg/dl with bleeding
Sickle Cell Trait
heterozygous, 10%
Sickle Cell Disease
homozygous
HIT Type 1
not immune mediated
onset 1-4 days
mild thrombocytopenia, resolves
usually high dose heparin
HIT Type 2
immune mediated onset 5-14 days severe thrombocytopenia usually low dose heparin associated with poor outcomes
Hemophilia A
FVIII deficiency
Hemophilia B
FIX deficiency